semaglutide gastroparesis lawsuit 2024 Ozempic [July 2026 Update] Ozempic Lawsuit for Gastroparesis |

The TRIUMPH-3 clinical trial for retatrutide began in April 2022 and enrolled adults with obesity who are at high risk for cardiovascular disease or heart disease

Semaglutide lowers body weight by reducing appetite and hunger, increasing satiety, reducing food cravings, altering food preferences, and reducing energy intake

Tesamorelin has the most robust evidence base , anchored by FDA approval and Phase 3 randomised controlled trials, particularly for visceral fat reduction

Clinical trials are underway to see whether the drugs can reduce the risk of heart attack, stroke, kidney disease and other chronic diseases in people with obesity

InjectCo's BriteBody program can include two types of GLP-1 medication, depending on what your provider determines is the right fit after reviewing your health history and weight loss goals